Strategic Partnerships Opportunity to expand robotic cochlear implantation capabilities via partnerships with pediatric and orthopedic device manufacturers like OrthoPediatrics, leveraging their distribution and clinical networks to reach CI candidates and hospitals.

Clinical Validation Strong differentiator in reducing intracochlear trauma and preserving hearing, supported by 2026 Laryngoscope data. Leverage this clinical edge to approach hospitals and ENT/otology centers emphasizing improved patient outcomes and surgeon confidence.

Board & Advisory Recent additions to leadership and scientific advisory board signal continued credibility. Target academic medical centers and grant-funded research programs for pilots, studies, and co-development with researchers.

Funding & Growth Series A funding and active hiring indicate a growth phase. Approach growth-stage investors and strategic buyers, and pursue hospital system partnerships that can scale adoption in multi-site networks.

Global Expansion International collaboration potential with leading otolaryngology centers and distributors. Position iotaSOFT for international trials and regulatory pathways to broaden market access beyond the United States.